TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06193928: Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)

Sponsor: Mirum Pharmaceuticals, Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 70 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,261,600

Rescue Site Savings

+$830,000

Unlock Full NCT06193928 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06193928 Rescue Dossier →